Investing guide, latest news & videos!
Live Last read · last published · next check
Cantor Fitzgerald has initiated coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with an overweight rating and a price target of $3.00, signaling significant upside potential for the biotechnology company. The firm announced the rating on Wednesday, with analyst Olivia Brayer Saunders leading the coverage initiation. The stock currently trades at $1.08, representing a 46.5% decline…
Analyst Upgrades Price Target Following Strong Fiscal Performance H.C. Wainwright raised its price target on DRDGOLD Ltd. (NYSE:DRD) to $35.00 from $33.00 while maintaining a Buy rating on the gold producer. The upgrade follows a banner year in which the company recorded revenue of R11,159 million, approximately $692.6 million, representing a 42% year-over-year increase. Net The post H.C.…
Arizona Pursues California Water Solutions The Water Infrastructure Finance Authority of Arizona approved more than $7 million for studies advancing two proposed water developments in California that could deliver new supplies into the state. The prospective plans would trade investments in Southern California groundwater storage and water recycling for a portion of the water that The post Arizona…
The landscape of large language model architecture shifted dramatically when context windows expanded from thousands to millions of tokens. An experiment pitting retrieval-augmented generation against full-corpus context delivery reveals that fitting everything into memory does not automatically translate into better performance, a finding with direct implications for traders building AI-assisted…
H.C. Wainwright has reaffirmed its Buy rating and $75.00 price target on UroGen Pharma (NASDAQ:URGN) following the company’s submission of a New Drug Application to the FDA for UGN-103. Analyst Ram Selvaraju maintained his bullish stance on the biotechnology company, citing strong clinical data and extended market exclusivity as key drivers for the stock’s continued The post H.C. Wainwright…
The Federal Reserve releases minutes from its July interest rate meeting Wednesday afternoon, offering crucial insight into a heated debate over monetary policy direction. The central bank kept rates steady in July, but three Fed officials dissented, advocating for higher borrowing costs to combat persistent inflation pressures. Market watchers now scramble to understand the depth The post Fed…
Treasury Yields Hit 17-Year Highs as Investors Reprice Risk The bond vigilantes are back, and equity markets are about to discover the cost, according to Nigel Green, CEO of global financial advisory firm deVere Group. Treasury yields have surged to levels not seen since 2007, with the 30-year US government borrowing rate now pushing above The post Bond Vigilantes Resurface as Yields Hit 17-Year…
Infleqtion, Inc. revised its second-quarter 2026 revenue upward five days after its original earnings announcement, a rare move that triggered a sell-off and exposed the accounting fragility beneath the quantum hardware company’s $2.79 billion market capitalization. The company disclosed at 7:20 p.m. ET Monday that Q2 2026 revenue climbed to $13.5 million from the $12.6 The post Infleqtion Revenue…
Gemini co-founder Cameron Winklevoss has cast the recent Bitcoin price decline as an unexpected opportunity, arguing that the artificial intelligence equity boom has effectively created a “time machine” for digital asset buyers. In an August 18 post on X, Winklevoss described the current $64,000 BTC level as an unprecedented entry point that represents roughly a The post Bitcoin Time Machine Hands…
H.C. Wainwright Maintains Bullish Stance on Depression Drug Developer H.C. Wainwright reiterated a Buy rating and $70 price target on Helus Pharma (NASDAQ:HELP) on Wednesday, positioning the biotech firm for a potential value inflection point as critical Phase 3 trial data approaches. The stock has surged 77% over the past year and currently trades at The post Helus Pharma Reaffirmed at Buy as…
A video published three years ago on YouTube can still be earning money today. Nobody had to make it again. No customer had to be reacquired. The production cost was paid years ago, but the cash flow continues. That makes old video libraries look a lot like annuities, and financial buyers are starting to take The post Private Equity Turns Creator Content Libraries Into Cash-Generating Annuities…
Annovis Bio shares received renewed attention from Wall Street this week as Canaccord Genuity Group reaffirmed its bullish stance on the biotechnology company. The investment firm reissued its buy rating on the stock in a research note released Tuesday, signaling continued confidence in the company’s prospects despite recent market volatility. The New York Stock Exchange-listed The post Annovis…